List of Excipients in Branded Drug SODIUM OXYBATE

Generic Drugs Containing SODIUM OXYBATE

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	sodium oxybate	31722-891	MALIC ACID
Camber Pharmaceuticals Inc	sodium oxybate	31722-891	WATER
Amneal Pharmaceuticals LLC	sodium oxybate	65162-065	MALIC ACID
Amneal Pharmaceuticals LLC	sodium oxybate	65162-065	PROPYLPARABEN SODIUM
Amneal Pharmaceuticals LLC	sodium oxybate	65162-065	SODIUM HYDROXIDE
Amneal Pharmaceuticals LLC	sodium oxybate	65162-065	WATER

What are the Most Frequently-Used Excipients in SODIUM OXYBATE?

# Of NDCs	Excipient
3	MALIC ACID
1	PROPYLPARABEN SODIUM
1	SODIUM HYDROXIDE
3	WATER

Sodium Oxybate Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Sodium oxybate has two distinct formulation markets: high-sodium immediate-release oral solutions and once-nightly extended-release products. The main commercial opportunity is not a new active ingredient. It is improved delivery, reduced sodium exposure, dosing convenience, palatability, abuse-resistance, and manufacturing efficiency.

Xyrem remains the reference immediate-release sodium oxybate product. Xywav uses a mixed-oxy­bate formulation to reduce sodium intake. Lumryz uses extended-release sodium oxybate microspheres to convert two nightly doses into one. Each product creates a different excipient and intellectual-property opportunity.

What products contain sodium oxybate?

Product	Company	Dosage form	Dosing profile	Key formulation issue
Xyrem	Jazz Pharmaceuticals	0.5 g/mL oral solution	Two doses per night	High sodium load, concentrated liquid, controlled distribution
Xywav	Jazz Pharmaceuticals	0.5 g/mL oral solution	Two doses per night	Lower sodium exposure, multi-oxy­bate salt system
Lumryz	Avadel Pharmaceuticals	Extended-release oral suspension powder	One dose at bedtime	Release control, dose uniformity, suspension performance
Generic sodium oxybate oral solutions	Multiple ANDA sponsors	0.5 g/mL oral solution	Two doses per night	Bioequivalence, REMS, formulation and commercial access
Future modified-release products	Potential entrants	Multiparticulates, tablets, suspensions, or liquid systems	One dose or reduced dosing burden	Patentability, abuse deterrence, high-dose manufacturability

Sodium oxybate is a small molecule. Biosimilar regulation does not apply. Competition proceeds through abbreviated new drug applications, 505(b)(2) applications, or full applications for materially different delivery systems.

What excipients are used in Xyrem and Xywav?

Xyrem and Xywav use aqueous, concentrated oral solutions. Their excipient burden is limited because the active ingredient is highly water-soluble and is administered at a large dose.

Xyrem excipient profile

Xyrem contains sodium oxybate in a concentrated oral solution. The product uses purified water and pH-adjusting excipients, including malic acid and sodium hydroxide, according to the FDA prescribing information.[1]

The formulation strategy prioritizes:

• High drug loading.
• Chemical stability in water.
• Accurate delivery through the supplied dosing device.
• Acceptable microbial control.
• Compatibility with controlled-distribution packaging.
• A reproducible pH and osmolality profile.

The product is diluted with water before administration. This reduces the need for flavoring or viscosity modification in the commercial concentrate, although taste remains a practical adherence issue.

Xywav excipient profile

Xywav contains four oxybate salts: calcium oxybate, magnesium oxybate, potassium oxybate, and sodium oxybate. The formulation reduces sodium exposure by replacing part of the sodium oxybate content with other cation salts.[2]

Its commercial differentiation depends on the active salt system rather than on a conventional excipient innovation. The excipient platform remains a relatively simple aqueous solution with pH-control components.

The sodium-reduction strategy is clinically relevant. The FDA label states that Xywav contains approximately 92% less sodium than an equivalent dose of Xyrem.[2] That creates a strong product-positioning advantage for patients with cardiovascular, renal, metabolic, or dietary sodium concerns.

Commercial implications for solution excipients

The immediate-release solution market offers limited room for conventional excipient differentiation. An ANDA sponsor generally must match the reference product closely enough to satisfy pharmaceutical equivalence and bioequivalence requirements.

The more valuable opportunities are:

1. Taste masking. Sweeteners, flavor systems, complexing agents, or bitterness suppressors may improve adherence, but must not materially alter absorption or stability.
2. Low-volume administration. Higher-concentration solutions could reduce dosing volume, but viscosity, dose-measurement error, osmolality, and precipitation become critical.
3. Sodium-reduced salt systems. This is a formulation and active-ingredient strategy rather than a conventional excipient strategy. Xywav demonstrates the commercial value of cation substitution.
4. Dosing-device optimization. Oral syringes, adapters, dose cups, and tamper-evident systems can create combination-product or packaging IP.
5. Abuse-deterrent systems. Bittering agents, gelling excipients, or dose-limiting packaging could support a differentiated 505(b)(2) product, but would require clinical and abuse-liability evidence.

What excipients are used in Lumryz?

Lumryz is a once-nightly extended-release sodium oxybate product. It is supplied as a powder for oral suspension and uses multiparticulate technology to release sodium oxybate over an extended period.[3]

The formulation uses functional excipients associated with coated particles and controlled release, including polymeric coating materials, matrix or carrier excipients, plasticizers, anti-tacking agents, and flow-control materials. The FDA labeling identifies excipient components including microcrystalline cellulose, ethylcellulose, hypromellose, methacrylic acid copolymer, triethyl citrate, talc, and colloidal silicon dioxide.[3]

Why Lumryz needs a different excipient platform

Sodium oxybate is highly water-soluble. A controlled-release product therefore faces a substantial formulation challenge: the active dissolves rapidly unless the dosage form creates a physical or chemical barrier.

The excipient system must control:

• Water penetration.
• Polymer swelling.
• Diffusion through the coating.
• Particle integrity during reconstitution.
• Suspension uniformity.
• Gastric and intestinal release.
• Dose delivery from a single prepared suspension.

The commercial value lies in maintaining a predictable oxybate exposure profile across the night without requiring a middle-of-the-night dose.

Lumryz formulation barriers

An entrant attempting to design around Lumryz would need to address several technical barriers:

Technical barrier	Formulation consequence
High nightly dose	Large mass of active and excipients
High water solubility	Need for robust release barriers
Powder reconstitution	Must disperse rapidly without clumping
Single-dose administration	Tight control of dose uniformity
Overnight pharmacokinetics	Release must remain within a defined time window
Sodium burden	Sodium exposure remains unless the salt system changes
Abuse potential	Rapid release or dose dumping creates safety concerns
Food effects	Release and absorption must remain clinically manageable

The high dose makes conventional tablets unattractive. A tablet containing 4.5 to 9 grams of sodium oxybate would be large, difficult to swallow, and difficult to manufacture with uniform release characteristics. Multiparticulates, granules, coated crystals, and liquid suspensions are more practical.

What excipient strategies have the strongest commercial potential?

1. Taste masking and adherence systems

Sodium oxybate solutions have a salty and unpleasant taste. The current administration process requires dilution, but taste can still affect adherence and willingness to continue treatment.

Potential technologies include:

• Ion-exchange resin complexes.
• Lipid or polymer microencapsulation.
• Bitterness suppressors.
• Taste-masking coatings.
• pH-controlled flavor systems.
• Ready-to-drink diluted presentations.
• Single-use sachets containing a measured flavor component.

The main development risk is that taste-masking materials may delay or reduce absorption. Any system that changes the free concentration of oxybate must be assessed for bioequivalence and pharmacokinetic impact.

2. Sodium-reduction platforms

The strongest demonstrated commercial opportunity is reduction of sodium exposure. Xywav establishes that patients and prescribers value a lower-sodium oxybate product.

Possible approaches include:

• Mixed calcium, magnesium, potassium, and sodium oxybate salts.
• Partial counterion substitution.
• Separate active-salt granules with controlled dissolution.
• Lower-sodium modified-release systems.
• Combination products that reduce total sodium without increasing potassium or magnesium risk.

This field is likely to attract composition-of-matter, salt-form, process, and method-of-use patents. The central regulatory issue is whether the product remains pharmaceutically equivalent to sodium oxybate or becomes a distinct active-moiety formulation requiring a 505(b)(2) pathway.

3. Once-nightly controlled release

Controlled-release sodium oxybate is the most valuable delivery opportunity because it addresses the core inconvenience of Xyrem and Xywav: the second nighttime dose.

Potential excipient platforms include:

• Ethylcellulose-coated multiparticulates.
• Enteric and pH-sensitive polymers.
• Hydrophilic matrix systems.
• Osmotic or diffusion-controlled particles.
• Layered granules with staggered release.
• Floating or gastric-retentive systems.
• Dual-population particles, with immediate-release and extended-release fractions.

The preferred design is likely a multiparticulate system that minimizes dose dumping and allows adjustment of the immediate-release and delayed-release fractions. A product with a different release mechanism could pursue 505(b)(2) approval if it demonstrates comparable efficacy and safety with a clinically meaningful dosing advantage.

4. Pediatric and geriatric presentations

Pediatric patients may benefit from:

• Premeasured unit-dose liquids.
• Improved flavor systems.
• Smaller administration volumes.
• Child-resistant but caregiver-friendly packaging.
• Dosing devices with integrated dose verification.

Older patients may benefit from lower-sodium formulations, simplified preparation, and reduced nighttime handling. Packaging and device patents may provide protection even when the formulation itself is difficult to patent.

5. Abuse-deterrent formulations

Sodium oxybate is a central nervous system depressant with abuse and misuse risks. The FDA-approved products are subject to restricted distribution and REMS controls.[1-3]

Potential abuse-deterrent approaches include:

• Gel-forming excipients that prevent rapid extraction.
• Bittering agents.
• Controlled-release particles resistant to crushing.
• Packaging that limits the quantity accessible at one time.
• Co-formulation with aversive agents.
• Tamper-evident dose preparation systems.

A formulation that reduces abuse potential may support product differentiation, but it would need evidence showing that the deterrent function remains effective without impairing therapeutic delivery.

What patents protect sodium oxybate products?

Sodium oxybate patent protection has historically covered several layers rather than a single molecule patent.

Patent categories

Patent category	Typical claim scope	Commercial relevance
Method of use	Treatment of narcolepsy, cataplexy, or excessive daytime sleepiness	Can delay generic use for specific indications
Dosing regimen	Nighttime dose splitting, titration, or administration schedule	Relevant to label carve-outs and litigation
Controlled distribution	Restricted pharmacy and dispensing systems	May support listed patents or regulatory exclusivity
Formulation	Extended release, multiparticulates, coating systems, or salt mixtures	Core protection for Lumryz and future products
Device and packaging	Dosing cups, syringes, unit-dose systems, and secure containers	Supports lifecycle management
Manufacturing	Granulation, coating, drying, and particle-size control	Creates process barriers and trade-secret value
Salt composition	Mixed oxybate salts and reduced-sodium systems	Central to Xywav-type products

The FDA Orange Book is the controlling public source for listed patents and regulatory exclusivity for approved drug products.[4] Xyrem has been subject to extensive patent litigation and Paragraph IV challenges involving generic sodium oxybate applicants. The disputes have addressed method-of-use, distribution controls, and product-specific patent claims.

Paragraph IV and generic-entry exposure

Generic sodium oxybate oral solutions face two separate obstacles:

1. Regulatory equivalence. The generic must demonstrate pharmaceutical equivalence, bioequivalence, and compliance with the applicable REMS or shared-system requirements.
2. Commercial access. A generic may receive FDA approval but remain constrained by patent settlements, restricted distribution requirements, or limited pharmacy participation.

A Paragraph IV certification is an assertion that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Litigation can delay approval or launch. A settlement may authorize entry on a negotiated date, sometimes before the listed patent expiration.

For immediate-release sodium oxybate, the principal long-term risk is erosion of Xyrem revenue through approved generics and authorized-generic channels. For Lumryz, the larger risk is product-specific formulation and method-of-use litigation because the value proposition depends on extended release.

What is the FDA regulatory status of sodium oxybate products?

Sodium oxybate products are FDA-approved for narcolepsy-related conditions, including cataplexy and excessive daytime sleepiness in appropriate patient populations.[1-3]

Regulatory issue	Xyrem	Xywav	Lumryz
FDA pathway	NDA	NDA	NDA
Active ingredient	Sodium oxybate	Mixed oxybate salts	Sodium oxybate
Release profile	Immediate	Immediate	Extended
REMS or restricted distribution	Yes	Yes	Yes
Biosimilar pathway	No	No	No
Generic pathway	ANDA	More difficult because of mixed salts and product-specific claims	Product-specific 505(b)(2) or other pathway likely
Main regulatory risk	Generic substitution and REMS access	Salt-system equivalence and safety	Dose-dumping, food effect, and overnight exposure

A lower-sodium product using different oxybate salts may not be a straightforward ANDA candidate. The active moiety, salt composition, pharmacokinetics, and clinical labeling determine the most practical regulatory route.

Which companies are challenging the sodium oxybate market?

Jazz Pharmaceuticals controls Xyrem and Xywav. Avadel Pharmaceuticals commercializes Lumryz. Generic drug companies have pursued sodium oxybate oral solutions through ANDA filings and Paragraph IV litigation.

The competitive field divides into four groups:

1. Reference-product suppliers: Jazz Pharmaceuticals.
2. Extended-release innovators: Avadel Pharmaceuticals.
3. Generic oral-solution manufacturers: Companies pursuing Xyrem-equivalent products.
4. Technology licensors and excipient developers: Suppliers of modified-release polymers, coated particles, taste-masking systems, and dosing devices.

Excipient suppliers can capture value without owning an approved sodium oxybate product. The most attractive licensing targets are controlled-release particle technology, low-sodium salt platforms, and abuse-deterrent delivery systems.

How strong is the sodium oxybate patent estate?

The estate is strongest where formulation performance is difficult to reproduce and clinically measurable.

Stronger protection

• Extended-release multiparticulates with defined release fractions.
• Specific polymer coating architectures.
• Mixed oxybate salt compositions with reduced sodium exposure.
• Once-nightly dosing regimens tied to pharmacokinetic performance.
• Manufacturing processes that produce narrow particle-size distributions.
• Integrated packaging and preparation systems.

Weaker protection

• Basic aqueous solutions.
• Generic flavoring or sweetening.
• Conventional pH adjustment.
• Broad claims to sodium oxybate treatment without formulation specificity.
• Standard oral syringes and containers.

Manufacturing know-how may be as important as issued patents. Coating uniformity, particle-size control, suspension behavior, and dose-to-dose release consistency can be difficult to replicate even when a competitor designs around the claims.

What generic launch scenarios exist for sodium oxybate?

Scenario 1: Immediate-release generic entry

Generic oral solution entry would place the greatest pressure on Xyrem. Price erosion would depend on the number of approved suppliers, REMS implementation, payer substitution, and the extent of authorized-generic competition.

Scenario 2: Limited generic substitution

A generic may be approved but achieve limited uptake because of restricted distribution, physician prescribing practices, specialty-pharmacy controls, or settlement terms.

Scenario 3: Low-sodium differentiated entry

A lower-sodium formulation could compete with Xywav through a 505(b)(2) application or a distinct NDA. Its commercial value would depend on sodium reduction, tolerability, and whether the formulation preserves the existing nighttime dosing schedule.

Scenario 4: Once-nightly controlled-release competition

A competing extended-release product could challenge Lumryz if it demonstrates comparable overnight control with lower dose volume, improved taste, lower sodium, or simpler preparation.

What commercial opportunities exist for excipient manufacturers?

The best opportunities are specialized rather than commodity-based.

Opportunity	Customer need	Potential protection
Controlled-release coatings	Once-nightly dosing	Formulation and process patents
Taste masking	Better adherence	Composition and use patents
Low-sodium salt systems	Reduced sodium exposure	Salt, composition, and method patents
Abuse-deterrent excipients	Lower misuse risk	Formulation and regulatory differentiation
Unit-dose packaging	Accurate and secure administration	Device and packaging patents
Reconstitution aids	Faster, cleaner preparation	Combination-product and packaging claims
Pediatric flavor systems	Improved caregiver administration	Formulation and device claims
Process aids	High-dose particle manufacturing	Trade secrets and process patents

The most defensible commercial position combines an excipient, a defined particle architecture, a manufacturing process, and a clinical outcome such as once-nightly dosing or reduced sodium exposure.

Key Takeaways

• Xyrem and Xywav are concentrated immediate-release solutions with relatively simple excipient systems.
• Xywav’s main differentiation is mixed oxybate salts and approximately 92% lower sodium exposure than Xyrem.
• Lumryz creates the strongest excipient opportunity because its commercial value depends on extended-release multiparticulates.
• Taste masking, sodium reduction, abuse deterrence, and dosing-device innovation are the leading adjacent opportunities.
• Sodium oxybate has no biosimilar pathway because it is a small molecule.
• Immediate-release generic competition creates the primary Xyrem revenue risk.
• Formulation, dosing-regimen, manufacturing, and packaging patents are more commercially important than basic solution excipients.
• Coated multiparticulates with reliable overnight release offer the most substantial licensing and technology opportunity.
• FDA approval does not alone guarantee rapid generic penetration because REMS, specialty distribution, patent settlements, and payer controls affect launch economics.

FAQs

Can sodium oxybate be formulated as a tablet?

A tablet is technically possible but commercially difficult because the nightly dose can reach 9 grams. Multiparticulate suspensions or high-load granules are more practical for swallowing, dose uniformity, and controlled release.

What is the most valuable excipient for extended-release sodium oxybate?

No single excipient determines performance. The highest-value platform is a controlled-release coating system, typically combining a film-forming polymer, plasticizer, anti-tacking agent, and carrier or matrix material.

Can a company patent a new flavor for sodium oxybate?

A flavor alone is usually weak patent subject matter. Stronger protection would connect the flavor system to a defined composition, improved palatability, stability, reduced dosing errors, or a clinically relevant adherence benefit.

Does a lower-sodium oxybate product automatically qualify as a generic?

No. A product using different oxybate salts or a different active-ingredient composition may require a 505(b)(2) application or NDA rather than a conventional ANDA.

Are excipient suppliers exposed to sodium oxybate patent litigation?

They can be exposed when their technology is incorporated into a product that allegedly infringes formulation or manufacturing claims. Supplier indemnities, freedom-to-operate analysis, and ownership of process improvements are important in licensing agreements.

References

1. U.S. Food and Drug Administration. (2023). Xyrem (sodium oxybate) oral solution: Prescribing information. Jazz Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2023). Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution: Prescribing information. Jazz Pharmaceuticals, Inc.

3. U.S. Food and Drug Administration. (2023). Lumryz (sodium oxybate) extended-release oral suspension: Prescribing information. Avadel Pharmaceuticals.

4. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2022). Risk evaluation and mitigation strategy for sodium oxybate products. FDA.